You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 3, 2025

AMRIX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Amrix, and when can generic versions of Amrix launch?

Amrix is a drug marketed by Teva Pharms Intl and is included in one NDA.

The generic ingredient in AMRIX is cyclobenzaprine hydrochloride. There are sixteen drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the cyclobenzaprine hydrochloride profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for AMRIX?
  • What are the global sales for AMRIX?
  • What is Average Wholesale Price for AMRIX?
Drug patent expirations by year for AMRIX
Drug Prices for AMRIX

See drug prices for AMRIX

Drug Sales Revenue Trends for AMRIX

See drug sales revenues for AMRIX

Pharmacology for AMRIX
Paragraph IV (Patent) Challenges for AMRIX
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
AMRIX Extended-release Capsule cyclobenzaprine hydrochloride 15 mg and 30 mg 021777 1 2008-08-11

US Patents and Regulatory Information for AMRIX

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Teva Pharms Intl AMRIX cyclobenzaprine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021777-001 Feb 1, 2007 AB RX Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Teva Pharms Intl AMRIX cyclobenzaprine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021777-002 Feb 1, 2007 AB RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 2 of 2 entries

Expired US Patents for AMRIX

ApplicantTradenameGeneric NameDosageNDAApproval DatePatent No.Patent Expiration
Teva Pharms Intl AMRIX cyclobenzaprine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021777-002 Feb 1, 2007 ⤷  Subscribe ⤷  Subscribe
Teva Pharms Intl AMRIX cyclobenzaprine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021777-002 Feb 1, 2007 ⤷  Subscribe ⤷  Subscribe
Teva Pharms Intl AMRIX cyclobenzaprine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021777-002 Feb 1, 2007 ⤷  Subscribe ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>Patent No.>Patent Expiration
Showing 1 to 3 of 3 entries

International Patents for AMRIX

See the table below for patents covering AMRIX around the world.

CountryPatent NumberTitleEstimated Expiration
World Intellectual Property Organization (WIPO) 2005048996 ⤷  Subscribe
>Country>Patent Number>Title>Estimated Expiration
Showing 1 to 1 of 1 entries

AMRIX Market Analysis and Financial Projection

Market Dynamics and Financial Trajectory for Amrix

Overview of Amrix

Amrix, a brand-name prescription medication, contains the active drug cyclobenzaprine, which is used to relieve certain muscle spasms in adults, often in conjunction with rest and physical therapy[2].

Market Size and Growth of Muscle Relaxant Drugs

The global muscle relaxant drugs market, within which Amrix operates, is experiencing significant growth. Here are some key metrics:

  • The global muscle relaxant drugs market was estimated at USD 4.16 billion in 2021 and is expected to reach around USD 6.80 billion by 2030, growing at a CAGR of 5.62% from 2022 to 2030[1].
  • Alternatively, another report estimates the market size to be USD 3.74 billion in 2022, expected to grow at a CAGR of 4.38% to reach USD 5.28 billion by 2030[3].

Distribution Channels and Market Segmentation

Distribution Channels

The muscle relaxant drugs market is segmented by distribution channels, with hospital pharmacies holding the highest revenue share. Here are the key distribution channels:

  • Hospital Pharmacy: Captured the highest revenue share of 46.76% in 2022 and is expected to expand at the fastest CAGR over the forecast period due to growing awareness and increasing clinical and hospital visits[3].
  • Retail Pharmacy: Expected to be the second largest distribution channel.
  • Online Pharmacy: Gaining prominence due to convenience, comfort, and flexibility[3].

Regional Outlook

The market is also segmented by region, with North America dominating the overall muscle relaxant drugs market:

  • North America: Held a share of 37.56% in 2022, driven by a well-established healthcare infrastructure, substantial healthcare expenditures, and a rising prevalence of illnesses requiring muscle relaxant treatment[3][4].

Financial Trajectory of Amrix

Cost and Pricing

Amrix, being a brand-name medication, is more expensive compared to its generic counterpart, cyclobenzaprine. The actual price depends on insurance plans, location, and the pharmacy used[2].

Revenue Contribution

While specific revenue figures for Amrix are not provided, it contributes to the overall growth of the muscle relaxant drugs market. The market's growth is driven by factors such as increasing clinical and hospital visits, a growing geriatric population, and advances in pharmaceutical research[3][4].

Competitive Landscape

Amrix competes in a market with several other muscle relaxant drugs, including those from companies like Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Hikma Pharmaceuticals, and Ipsen Biopharmaceuticals Inc.[1].

Factors Driving Market Growth

Increasing Prevalence of Musculoskeletal Diseases

The rise in musculoskeletal diseases and chronic pain issues, partly due to sedentary lifestyles, rising sports and accident injuries, and an aging population, drives the demand for muscle relaxant medications like Amrix[4].

Advances in Pharmaceutical Research

Manufacturers are focusing on developing drugs with better safety profiles and fewer side effects, which is aiding the growth of the muscle relaxant market[4].

Regional Growth

The Asia Pacific region is expected to witness the fastest growth due to a rapidly aging population and changing lifestyles. Countries like Japan, China, and South Korea are at the forefront of this growth[3][4].

Side Effects and Safety Profile

Amrix, like other muscle relaxants, comes with several side effects, including:

  • Digestive Problems: Constipation, nausea, and indigestion are common side effects[2].
  • Blurry Vision: Although not reported in clinical studies of Amrix, it has been reported in people taking immediate-release forms of cyclobenzaprine[2].
  • Other Adverse Reactions: Dry mouth, dizziness, fatigue, somnolence, and more have been reported in clinical trials[5].

Conclusion

The market for muscle relaxant drugs, including Amrix, is poised for significant growth driven by increasing demand for treatments of musculoskeletal diseases and chronic pain. The financial trajectory of Amrix is tied to the overall growth of this market, with factors such as advances in pharmaceutical research, growing geriatric populations, and expanding distribution channels contributing to its revenue.

Key Takeaways

  • The global muscle relaxant drugs market is expected to grow significantly, reaching USD 6.80 billion by 2030.
  • Hospital pharmacies dominate the distribution channels for muscle relaxant drugs.
  • North America holds the largest market share due to its well-established healthcare infrastructure.
  • Amrix, containing cyclobenzaprine, is a key player in this market but is more expensive than its generic counterpart.
  • The market is driven by increasing prevalence of musculoskeletal diseases and advances in pharmaceutical research.

FAQs

  1. What is Amrix used for? Amrix is used to relieve certain muscle spasms in adults, often in conjunction with rest and physical therapy[2].

  2. How does the cost of Amrix compare to its generic form? Amrix costs much more than the generic form of cyclobenzaprine, with the actual price depending on insurance plans, location, and the pharmacy used[2].

  3. What are the common side effects of Amrix? Common side effects include digestive problems like constipation, nausea, and indigestion, as well as dry mouth, dizziness, fatigue, and somnolence[2][5].

  4. Which region dominates the muscle relaxant drugs market? North America dominates the overall muscle relaxant drugs market due to its well-established healthcare infrastructure and substantial healthcare expenditures[3][4].

  5. What factors are driving the growth of the muscle relaxant drugs market? The growth is driven by increasing prevalence of musculoskeletal diseases, advances in pharmaceutical research, and a growing geriatric population[3][4].

Sources

  1. Vision Research Reports - Muscle Relaxant Drugs Market Size, Share, Growth, Trends
  2. Medical News Today - Amrix: Dosage, side effects, alternatives, uses, and more
  3. Grand View Research - Muscle Relaxant Drugs Market Size & Share Report, 2030
  4. Verified Market Research - Muscle Relaxant Drugs Market Size, Share, Trends & Forecast
  5. FDA - AMRIX (cyclobenzaprine hydrochloride) - accessdata.fda.gov

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.